Impact of Route of Estrogen Administration on Bone Turnover Markers in Oligoamenorrheic Athletes and Its Mediators
- 23 November 2018
- journal article
- research article
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 104 (5) , 1449-1458
Abstract
Objective: Transdermal, but not oral, estrogen replacement improves bone mineral density (BMD) in athletes with oligoamenorrhea (OA). Our objective was to determine mechanisms that may explain the impact of route of estrogen administration on bone outcomes. Methods: Seventy-three participants with OA between 14 and 25 years old received (i) a 17β-estradiol transdermal patch continuously with cyclic oral micronized progesterone (PATCH), (ii) a combined ethinyl estradiol and desogestrel pill (PILL), or (iii) no estrogen/progesterone (NONE) for 12 months. We evaluated morning fasting levels of a marker of bone formation [N-terminal propeptide of type 1 procollagen (P1NP)], a marker of bone resorption (N-telopeptide), IGF-1, insulinlike growth factor binding protein 3, total testosterone, estradiol, SHBG, sclerostin, preadipocyte factor-1 (Pref-1), brain-derived neurotrophic factor (BDNF), calcium, 25(OH) vitamin D, and PTH levels at baseline and 12 months. Results: Groups did not differ for age, weight, exercise activity, or markers of bone formation at baseline. Over 12 months, P1NP decreased the most in the PILL group (P = 0.03) associated with a decrease in IGF-1 levels (r = 0.37; P = 0.003). Sclerostin, Pref-1, and BDNF decreased in the PATCH group over 12 months. PATCH had the greatest increases in estradiol (P ≤ 0.0001), and estradiol increases were associated with increases in bone density. Conclusion: Transdermal 17β-estradiol given over 12 months does not cause the decrease in IGF-1 observed with oral ethinyl estradiol. It also leads to decreases in sclerostin, Pref-1, and BDNF, which may mediate the beneficial effects of estrogen.Keywords
Funding Information
- National Institutes of Health (R01HD060827, K24HD071843, K23DK110419, UL1TR001102, P30DK040561)
This publication has 46 references indexed in Scilit:
- Inhibition of BDNF in Multiple Myeloma Blocks Osteoclastogenesis via Down-Regulated Stroma-Derived RANKL Expression Both In Vitro and In VivoPLOS ONE, 2012
- Preadipocyte Factor-1 Levels Are Higher in Women with Hypothalamic Amenorrhea and Are Associated with Bone Mineral Content and Bone Mineral Density through a Mechanism Independent of LeptinThe Journal of Clinical Endocrinology & Metabolism, 2011
- Effects of estrogen on osteoprogenitor cells and cytokines/bone-regulatory factors in postmenopausal womenBone, 2011
- Physiologic estrogen replacement increases bone density in adolescent girls with anorexia nervosaJournal of Bone and Mineral Research, 2011
- Estrogen inhibits Dlk1/FA1 production: A potential mechanism for estrogen effects on bone turnoverJournal of Bone and Mineral Research, 2011
- Regulation of circulating sclerostin levels by sex steroids in women and in menJournal of Bone and Mineral Research, 2010
- Effects of Recombinant Human Growth Hormone in Anorexia Nervosa: A Randomized, Placebo-Controlled StudyThe Journal of Clinical Endocrinology & Metabolism, 2010
- Preadipocyte Factor-1 Is Associated with Marrow Adiposity and Bone Mineral Density in Women with Anorexia NervosaThe Journal of Clinical Endocrinology & Metabolism, 2010
- Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statementCytotherapy, 2006
- Response of Biochemical Markers of Bone Turnover to Hormone Replacement Therapy: Impact of Biological VariabilityJournal of Bone and Mineral Research, 1998